Insights into Spinal Muscular Atrophy Pipeline 2023: Analysis of Clinical Trials, Pipeline Therapies, Treatment, and Companies in 2023-Exploring Drugs, Mechanisms of Action, Routes of Administration, and Recent Developments by DelveInsight

Spinal Muscular Atrophy pipeline constitutes 10+ key companies continuously working towards developing 10+ Spinal Muscular Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Spinal Muscular Atrophy Pipeline Insight, 2023″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market.

The Spinal Muscular Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

To know more in detail about Spinal Muscular Atrophy pipeline report offerings, click here: https://www.delveinsight.com/report-store/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Spinal Muscular Atrophy Overview
Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disorder that affects the motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. It is caused by a deficiency in the survival motor neuron (SMN) protein due to mutations in the SMN1 gene. Spinal Muscular Atrophy is classified into different types based on age of onset and severity, with type 1 being the most severe and typically presenting in infancy.

The condition results in difficulty with basic motor functions such as crawling, sitting, and walking, and can lead to respiratory and swallowing difficulties in more severe cases. While there is currently no cure for Spinal Muscular Atrophy, advances in medical treatment, including gene therapy and medication such as nusinersen, have shown promising results in slowing disease progression and improving quality of life for those affected. Early diagnosis and comprehensive care are crucial to managing the condition effectively.

Some of the key takeaways from the Spinal Muscular Atrophy Pipeline Report:
• Companies across the globe are diligently working toward developing novel Spinal Muscular Atrophy treatment therapies with a considerable amount of success over the years. Spinal Muscular Atrophy Key players such as - Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Genethon, Astellas Pharma, Hoffmann-La Roche, and others, are developing therapies for the Spinal Muscular Atrophy treatment
• Spinal Muscular Atrophy emerging therapies such as - ACTX-401, Apitegromab, and others are expected to have a significant impact on the Spinal Muscular Atrophy market in the coming years.
• On July 2023, Novartis Pharmaceuticals announced an open-label, single arm, multi-centre study to evaluate the safety, tolerability and efficacy of IV OAV101 in SMA participants. The study will enroll participant's ≤ 24 months that weigh ≤ 17 kg. Participants will receive a single administration of IV OAV101 at the approved dose of 1.1e14 vg/kg.
• On May 2023, Biogen announced a study on Spinal Muscular Atrophy. The primary objective of the study is to describe the natural history and utilization of disease modifying therapy (DMT) among adult Chinese participants with SMA linked to chromosome 5q (5q-SMA).

To know in detail about the Spinal Muscular Atrophy clinical trials and recent FDA approvals for Spinal Muscular Atrophy drugs, click here: https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Spinal Muscular Atrophy Pipeline Therapeutics Assessment
• Spinal Muscular Atrophy Assessment by Product Type
• Spinal Muscular Atrophy By Stage and Product Type
• Spinal Muscular Atrophy Assessment by Route of Administration
• Spinal Muscular Atrophy By Stage and Route of Administration
• Spinal Muscular Atrophy Assessment by Molecule Type
• Spinal Muscular Atrophy by Stage and Molecule Type

DelveInsight's Spinal Muscular Atrophy Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Spinal Muscular Atrophy Drugs Under Different Phases of Clinical Development Include:
• ACTX-401: Novartis
• Apitegromab: Scholar Rock
• GYM329: Roche
• And Many Others

Get a Free Sample PDF Report to know more about Spinal Muscular Atrophy Pipeline Assessment: https://www.delveinsight.com/report-store/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Spinal Muscular Atrophy Pipeline Analysis:
The Spinal Muscular Atrophy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Spinal Muscular Atrophy treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment.
• Spinal Muscular Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Spinal Muscular Atrophy product details are provided in the report. Download the Spinal Muscular Atrophy pipeline report to learn more about the emerging Spinal Muscular Atrophy therapies: https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of Spinal Muscular Atrophy Pipeline Drug Insight
• Coverage: Global
• Key Spinal Muscular Atrophy Companies: Acurastem, Everfront Biotech Co., Ltd, Eledon Pharmaceuticals, AL-S Pharma, Novartis, Annexon Biosceinces, MediciNova, Treeway, Biogen, and others
• Key Spinal Muscular Atrophy Therapies: AS-202, HK001, Tegoprubart, AP-101, BLZ945, ANX005, MN-166, TW001, BIIB067, and others
• Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies
• Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers

Table of Contents
1 Spinal Muscular Atrophy Report Introduction
2 Spinal Muscular Atrophy Executive Summary
3 Spinal Muscular Atrophy Overview
4 Spinal Muscular Atrophy- Analytical Perspective In-depth Commercial Assessment
5 Spinal Muscular Atrophy Pipeline Therapeutics
6 Spinal Muscular Atrophy Late Stage Products (Phase II/III)
7 Spinal Muscular Atrophy Mid Stage Products (Phase II)
8 Spinal Muscular Atrophy Early Stage Products (Phase I)
9 Spinal Muscular Atrophy Preclinical Stage Products
10 Spinal Muscular Atrophy Therapeutics Assessment
11 Spinal Muscular Atrophy Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Spinal Muscular Atrophy Key Companies
14 Spinal Muscular Atrophy Key Products
15 Spinal Muscular Atrophy Unmet Needs
16 Spinal Muscular Atrophy Market Drivers and Barriers
17 Spinal Muscular Atrophy Future Perspectives and Conclusion
18 Spinal Muscular Atrophy Analyst Views
19 Appendix
20 About DelveInsight

Trending Report:
• Hiatal Hernia Market: https://www.delveinsight.com/report-store/hiatal-hernia-market
• Lhon Market: https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
• Reactive Arthritis Market: https://www.delveinsight.com/report-store/reactive-arthritis-market
• Vascular Dementia Market: https://www.delveinsight.com/report-store/vascular-dementia-market
• Acquired Hemophilia A Pipeline: https://www.delveinsight.com/report-store/acquired-hemophilia-a-pipeline-insight
• Acute Gout Flare Market: https://www.delveinsight.com/report-store/acute-gout-flare-market
• Adrenal Insufficiency Market: https://www.delveinsight.com/report-store/adrenal-insufficiency-market
• Alkaptonuria Market: https://www.delveinsight.com/report-store/alkaptonuria-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Central Serous Chorioretinopathy Market: https://www.delveinsight.com/report-store/central-serous-chorioretinopathy-market
• Chronic Idiopathic Urticaria Market: https://www.delveinsight.com/report-store/chronic-idiopathic-urticaria-market
• Contusion Market: https://www.delveinsight.com/report-store/contusion-market
• Heavy Metal Poisoning Markets: https://www.delveinsight.com/report-store/heavy-metal-poisoning-market
• Microsatellite Stable Colorectal Cancer Market: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market
• Phosphoglucomutase Pgm 1 Deficiency Market: https://www.delveinsight.com/report-store/phosphoglucomutase-pgm-1-deficiency-market
• Polypoidal Choroidal Vasculopathy Market: https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market
• Progressive Familial Intrahepatic Cholestasis Market: https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market
• Pulmonary Hypertension Associated With Interstitial Lung Disease Market: https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market
• Upper Limb Hypertonia Market: https://www.delveinsight.com/report-store/upper-limb-hypertonia-market
• Vestibular Schwannoma Market: https://www.delveinsight.com/report-store/vestibular-schwannoma-market
• Advanced Hepatocellular Carcinoma With Cpb Liver Cirrhosis Market: https://www.delveinsight.com/report-store/advanced-hepatocellular-carcinoma-with-cpb-liver-cirrhosis-market-insight
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Ankylosing Spondylitis Bekhterevs Disease Market: https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market
• Atypical Hemolytic Uremic Syndrome Ahus Market: https://www.delveinsight.com/report-store/atypical-hemolytic-uremic-syndrome-ahus-market
• Apraxia Market: https://www.delveinsight.com/report-store/apraxia-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Hallux Valgus Market: https://www.delveinsight.com/report-store/hallux-valgus-market
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Kidney Transplant Rejection Market: https://www.delveinsight.com/report-store/kidney-transplant-rejection-market
• Nmibc Market: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market
• T-cell-prolymphocytic Leukemia Market: https://www.delveinsight.com/report-store/t-cell-prolymphocytic-leukemia-market
• Adult Onset Still Disease Market: https://www.delveinsight.com/report-store/adult-onset-still-disease-market
• Biliary Tract Cancer Market: https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
• Triple Negative Breast Cancer Market: https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market
• Ventricular Dysfunction Market: https://www.delveinsight.com/report-store/ventricular-dysfunction-market
• Diffuse Cutaneous Systemic Sclerosis Market: https://www.delveinsight.com/report-store/diffuse-cutaneous-systemic-sclerosis-dcssc-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/report-store/pemphigus-vulgaris-market
• Helicobacter Pylori Infections Market: https://www.delveinsight.com/report-store/helicobacter-pylori-h-pylori-infection-market
• Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Acral Lentiginous Melanoma Market: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-market
• Bronchial Spasms Market: https://www.delveinsight.com/report-store/bronchial-spasm-market
• Chronic Cutaneous Ulcer Market: https://www.delveinsight.com/report-store/chronic-cutaneous-ulcer-market
• Chronic Gout Market: https://www.delveinsight.com/report-store/chronic-gout-market
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
• Fibrocystic Breast Condition Market: https://www.delveinsight.com/report-store/fibrocystic-breast-condition-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market
• Leber's Hereditary Optic Neuropathy Market: https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
• Malt Lymphoma Market: https://www.delveinsight.com/report-store/malt-lymphoma-market
• Meningioma Market: https://www.delveinsight.com/report-store/meningioma-market
• Partial Seizure Market: https://www.delveinsight.com/report-store/partial-seizure-market
• Radiation Toxicity Market: https://www.delveinsight.com/report-store/radiation-toxicity-market
• Rhino Conjunctivitis Market: https://www.delveinsight.com/report-store/rhino-conjunctivitis-market

Contact Us:
Ankit Nigam
Assistant Manager Marketing
info@delveinsight.com
https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.